论文部分内容阅读
目的:探讨化疗结束时n 18F-FDG PET/CT Lugano淋巴瘤疗效评估标准与弥漫性大B细胞淋巴瘤(DLBCL)患者预后的关系。n 方法:回顾性分析2013年7月至2021年1月于河北医科大学第四医院诊治并于化疗结束时行n 18F-FDG PET/CT的DLBCL患者131例[男63例、女68例，年龄(50.3±17.0)岁]，利用n 18F-FDG PET/CT Lugano淋巴瘤疗效评估标准进行疗效评价[分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)]，随访患者的无进展生存(PFS)和总生存(OS)。采用Kaplan-Meier生存分析对临床参数和影像参数进行单因素分析，采用Cox比例风险回归模型进行多因素分析，探讨影响DLBCL患者预后的相关因素。n 结果:中位随访35.47个月，131例患者的5年PFS率为57.3%(75/131)，5年OS率为84.0%(110/131)；CR 74例，PR 37例，PD 20例。单因素分析示Lugano淋巴瘤疗效评估标准是PFS和OS的影响因素(PFS, n χ2＝72.25, n P<0.001；OS,n χ2＝11.97, n P＝0.003)；DLBCL患者Deauville评分(DS)是PFS(n χ2＝62.46, n P<0.001)和OS(n χ2＝19.95, n P<0.001)的影响因素；Ann Arbor分期、东部肿瘤协作组体能状态(ECOG PS)评分、国际预后指数(IPI)为PFS的影响因素(n χ2值：10.31~15.80，均n P<0.05)；Ann Arbor分期、ECOG PS评分、结外器官受累数目、βn 2微球蛋白、IPI为OS的影响因素(n χ2值：4.97~30.57，均n P<0.05)。Cox多因素分析示，Lugano淋巴瘤疗效评估标准、Ann Arbor分期和ECOG PS评分是PFS[相对危险度(n RR)及95% n CI：8.841(4.764~16.405)、1.434(1.111~1.852)、2.125(1.205~3.746)，n P值：<0.001、0.006和0.009]和OS[n RR(95% n CI)：3.276(1.304~8.235)、9.728(2.216~42.669)、2.506(1.040~6.039)，n P值：0.012、0.003和0.041]的预后因素。n 结论:化疗结束时n 18F-FDG PET/CT Lugano淋巴瘤疗效评估标准可以准确评估DLBCL患者预后。n “,”Objective:To investigate the relationship between n 18F-FDG PET/CT Lugano lymphoma response evaluation criteria and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) at the end of chemotherapy.n Methods:A total of 131 patients with DLBCL (63 males, 68 females, age (50.3±17.0) years) who underwent n 18F-FDG PET/CT at the end of chemotherapy in the Fourth Hospital of Hebei Medical University from July 2013 to January 2021 were analyzed retrospectively. n 18F-FDG PET/CT Lugano lymphoma response evaluation criteria was used to evaluate the response (complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD)). Progression-free survival (PFS) and overall survival (OS) were followed up. Kaplan-Meier survival analysis was used for univariate analysis of clinical parameters and imaging parameters, and Cox proportional hazards regression model was used for multivariate analysis to explore related factors affecting the prognosis of patients with DLBCL.n Results:The median follow-up time was 35.47 months for 131 patients with DLBCL. The 5-year PFS rate was 57.3%(75/131), and the 5-year OS rate was 84.0%(110/131). There were 74 cases of CR, 37 cases of PR and 20 cases of PD. Univariate analysis showed that the Lugano lymphoma response evaluation criteria was the influencing factor of PFS and OS (PFS, n χ2=72.25, n P<0.001; OS,n χ2=11.97, n P=0.003). Deauville score (DS) of patients with DLBCL was also the influencing factor for PFS (n χ2=62.46, n P<0.001) and OS (n χ2=19.95, n P<0.001). Ann Arbor stage, Eastern Cooperative Oncology Group physical state (ECOG PS) score and international prognostic index (IPI) were the influencing factors for PFS (n χ2 values: 10.31-15.80, all n P<0.05). Ann Arbor stage, ECOG PS score, number of extranodal organ involved, βn 2 microglobulin, and IPI were the influencing factors for OS (n χ2 values: 4.97-30.57, all n P<0.05). Cox multivariate analysis showed that Lugano lymphoma response evaluation criteria, Ann Arbor stage and ECOG PS score were independent prognostic factors for PFS (relative risk (n RR) and 95% n CI: 8.841(4.764-16.405), 1.434(1.111-1.852), 2.125(1.205-3.746), n P values: <0.001, 0.006, 0.009) and OS ( n RR(95% n CI): 3.276(1.304-8.235), 9.728(2.216-42.669), 2.506(1.040-6.039), n P values: 0.012, 0.003, 0.041).n Conclusion:18F-FDG PET/CT Lugano lymphoma response evaluation criteria can precisely evaluate the prognosis of patients with DLBCL at the end of chemotherapy.n